Dr Reddy’s Laboratories and its subsidiary, Promius Pharma today announced filing of three new drug applications (NDAs) with the US Food and Drug Administration.
Of the three, two are related to dermatology (skincare) applications and one is a corticosteroid, the company said in a filing to the BSE today.
Raghav Chari, Executive Vice President of Proprietary Products at Dr Reddy’s and President of Primus Pharma said “These products represent new, compelling options for segments of patients suffering from Psoriasis, Rosacea and Migraine”.
They are also the first of a large basket of products targeting conditions predominantly treated by dermatologist and neurologists. Upon approval, the products will be commercialised by Promius Pharma.
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…